🤖 AI Wearables for Managing Diabetes ~

In this paper - Fraser et al., 2025 - Researchers reviewed 60 studies on AI-powered wearables - continuous glucose monitors (CGMs), for Type 2 diabetes care. The tech is advancing fast—but major gaps remain before it reaches your doctor's office.

What's New:

Smarter Glucose Prediction: Deep learning models,particularly LSTMs and transformers, can predict blood sugar swings 30-120 minutes ahead of time by spotting patterns humans miss. One model achieved R² = 0.989 accuracy, essentially forecasting your glucose curve in real-time.

AI That Acts, Not Just Predicts: We're moving from forecasting to actual intervention. Reinforcement learning models, like Warren et al., 2024 now can suggest insulin doses autonomously, with results showing HbA1c drops by 1.3%.

Non-Invasive Hacks: Researchers are ditching finger pricks entirely—using smartphone photoplethysmography (PPG), ECG signals, even tear fluid infrared sensors to estimate glucose. One PPG-based deep learning model reached 90.6% accuracy for diabetes detection.

The AI Toolkit Deep-Dive:

>> LSTMs & GRUs (45% of studies): These recurrent neural networks are the workhorses—they process CGM time-series data sequentially, remembering past glucose values to predict future trends.

>> Transformers: They use "attention mechanisms" to weigh which past data points matter most — handling longer prediction windows across diverse populations better than LSTMs.

>> Temporal Fusion Transformers: Combine static data (age, BMI) with time-varying data (glucose, heart rate) in one model. Emerging but promising for personalized predictions.

>> Multi-Agent Reinforcement Learning (MARL): Multiple AI agents compete to identify which patient features (lab values, meds, demographics) most predict adverse glycemic events in hospitals. One study achieved 92.8% precision for hypoglycemia detection.

>> XGBoost & Random Forests: Traditional machine learning still dominates when doctors need interpretability. XGBoost ranked features by importance (SHAP values), showing clinicians why the AI flagged a patient as high-risk.

>> Deep-Ensemble Learning: Stacks multiple neural networks together—CNNs for pattern recognition, BiLSTMs for sequence memory, meta-learners for combining outputs.

Despite the great advances made, there are still some hard truths to tackle:

• 60% use "black box" models that doctors can't explain - the pattern is unknown.

• Only 7% report race/ethnicity data.

• Most studies are tiny (median 150 people).

• No long-term follow-ups exist - What would we see in 1 year's time?

The authors close off the review --- The tech works in pilots but we need diverse data, transparent models, and real-world validation before this becomes standard care.